The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...
HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...
Results from cohort 3 of ZUMA-2 demonstrated high objective response rates and deep remissions with a safety profile consistent with previous experience for this personalized immunotherapy. The Food ...
Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.
The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. GZR4 (Gan ...
More participants felt "much more" in control of their diabetes, eating, and weight after switching to tirzepatide vs escalating dulaglutide. HealthDay News — For adults with type 2 diabetes (T2D) who ...
The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.
Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence ...
Adding durvalumab and tremelimumab-actl to lenvatinib and transarterial chemoembolization significantly improved progression free survival in patients with unresectable hepatocellular carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results